Switching to Bortezomib may Improve Recovery From Severe Vincristine Neuropathy in Pediatric Acute Lymphoblastic Leukemia

Jaitri Joshi(Children's Minnesota), Bruce Bostrom(Minnesota West Community & Technical College), Laura Gilchrist(University of Namibia), Lynn Tanner(University of Namibia)
Journal of Pediatric Hematology/Oncology
June 25, 2019
10.1097/mph.0000000000001529
Cited by 7

Related Papers

A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study
|Blood|2002|496
Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group
|Blood|2003|361
Comparison of Autologous and Allogeneic Bone Marrow Transplantation for Treatment of High-Risk Refractory Acute Lymphoblastic Leukemia
|New England Journal of Medicine|1987|334
Juvenile xanthogranuloma: Forms of systemic disease and their clinical implications
|The Journal of Pediatrics|1996|294
Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study
|Journal of Clinical Oncology|2009|278